Home › IPO › Molbio Diagnostics Ltd
MainLine NSE • BSE Financial Services

Molbio Diagnostics Ltd IPO

Tech-led NBFC delivering AI/ML driven retail credit across Tier-2 & Tier-3 India.

Listed
Price Band ₹807 per share per share
Lot Size 18 Shares
Min. Investment ₹14526
Issue Size ₹939.7 Cr
Face Value ₹1
IPO Open 10 August 2026
IPO Close 12 August 2026
Allotment 13 Aug 2026
Listing 17 Aug 2026
Apply for IPO
Live demand

Subscription status for Molbio Diagnostics Ltd IPO

As of 02 May 26, 5:00 PM. Will get Updated in every 30 minutes

QIB 3.42x

Qualified Institutional Buyers

NII 2.15x

Non-Institutional Investors

Retail 1.84x

Retail Individual Investors

Total 2.48x

Across all investor categories

Key dates

IPO schedule for Molbio Diagnostics Ltd

From the day bidding opens to listing — every milestone you need to track.

IPO Open 10 Aug 2026
IPO Close 12 Aug 2026
Allotment 13 Aug 2026
Refund / Unblock 14 Aug 2026
Listing 17 Aug 2026
About the company

Who is Molbio Diagnostics Ltd ?

Molbio Diagnostics Limited was originally incorporated as Molbio Diagnostics Private Limited' at Panaji, as a private company dated October 20, 2000. Thereafter, Company was converted from a private limited company to a public limited company, and the name of Company was changed to Molbio Diagnostics Limited, and a fresh certificate of incorporation dated January 16, 2025 was issued to Company by the RoC.

Company is innovative point-of-care (POC) diagnostics company focused on expanding access to accurate, rapid and cost-effective healthcare technologies to diagnose infectious and non-communicable diseases. The Company entered into a joint venture agreement in August, 2011 with Bigtec Innovations Private Limited and Bigtec Private Limited, which started operations in 2000. Bigtec Innovations Private Limited got merged with the Company in 2015. It has developed Truenat' platform in 2015, which is a novel POC polymerase chain reaction (PCR) platform that can operate in resource limited settings since its battery operated, facilitating decentralized diagnosis within an hour.

The Company works five manufacturing facilities in India, of which two are in Goa, one in Bengaluru, Karnataka and one in Visakhapatnam, Andhra Pradesh. Company is mainly engaged in the business of manufacturing chip based diagnostic devices, chips and reagents, X-ray equipment's, single / dual detector solutions, developing diagnostic devices, performing tests in the bio-sensing domain, digital pathology, etc.

In addition to this, it offer products globally to public health programs, diagnostic laboratories, and private and public hospitals.

In February 2023, Company acquired 65.47% of the equity share capital of Prognosys Medical Systems Pvt Ltd to venture into radiology equipment. Further, in October 2024, Company acquired a 19.68 % equity stake in OptraScan Inc., a USA based company, to diversify to digital pathology scanners.

Company is planning to raise Rs 200 Cr fresh issue equity shares by way of initial public offer and by issuing 12,556,000 equity shares of Re 1 each through offer for sale.

Financial track record

Financials at a glance

Three-year trajectory of revenue, profit and assets — restated as per the RHP.

Revenue PAT Total Assets
FY 2025
FY 2024
FY 2023
Metric (₹ Cr)FY 2025FY 2024FY 2023
Total Income977.60762.84334.67
EBITDA223.21183.0948.19
PAT139.82111.1115.55
AUM1,307.471,077.20919.54

Strengths & Risks

A balanced look at what works in the company's favour and what investors should watch.

Strengths

  • We are well placed to address unmet demand in a large and growing molecular diagnostic market with gaining credence of point-of-care testing.
  • Innovative, R&D focussed business.
  • We have developed and commercialized a novel portable multi-disease point-of-care molecular diagnostics platform.
  • We have a scalable business model with strong entry barriers, high proportion of recurring revenues and a growing suite of tests.
  • Our strategic collaborations and acquisitions enhance our capabilities and offerings.
  • We have a management team with deep domain expertise and track record of delivering strong financial performance.

Risks

  • The company derives a portion of its revenues from the sale of the company's products to the Indian central and state governments, and international aid agencies for their public healthcare programs. The company's revenue from such government and international aid agencies was 84.56%, 87.83% and 91.60% of its revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. Any unfavourable policy changes by these agencies or a decrease in funding for public healthcare programs may impact the sale of the company's products and adversely affect its business, financial condition, results of operations and cash flows. Further, the company's revenue from the top 10 customers was 83.26%, 83.62% and 78.54% of its revenue from contracts with customers - sale of products - finished goods in Fiscals 2026, 2025 and 2024, respectively. The loss of any of these customers or a decline in demand for the company's products from them could also have an adverse effect on its business, financial condition, results of operations and cash flows.
  • The company derives a portion of its revenues from the sale of diagnostic test kits for tuberculosis ("TB"). Its revenue from the sale of test kits for TB was 70.20%, 69.11% and 62.40% of the company's revenue from contracts with customers - sale of products - finished goods in the Fiscals 2026, 2025 and 2024, respectively. Any decline in the demand for such test kits may have an adverse effect on the company's business, financial condition, results of operation and cash flows.
  • The company has invested and intend to continue to invest in research and development ("R&D") efforts to grow its menu of tests. The company cannot assure you that its R&D efforts will result in the successful development and obtaining of government approvals for new tests, which could adversely affect its business, results of operations, and cash flows.
  • The company's Subsidiaries, Prognosys Medical Systems Private Limited, Prognosys Healthcare (India) Private Limited and OptraScan INC, have incurred losses in the past and may incur losses in the future which could have an adverse effect on its business, financial condition, results of operations and cash flows. Further, the Company (on a consolidated basis) and some of its Subsidiaries have experienced negative cash flows from operating activities in the past. Any such negative cash flows in the future could affect the company's business, results of operations, financial condition and cash flows.
  • The company's Promoters (certain of whom are also Directors) hold Equity Shares in the Company and may be interested in the Company's performance in addition to any remuneration and reimbursement of expenses payable to them.
  • If the company is unable to patent new processes and protect its proprietary information or other intellectual property, the company's business may be adversely affected.
  • The company's Statutory Auditors' audit reports on its audited consolidated financial statements for Fiscals 2026, 2025 and 2024 includes emphasis of matter paragraph, modifications for certain matters specified in the report on other legal and regulatory requirements and certain qualifications under the reporting requirements under the Companies (Auditor's Report) Order, 2020 and Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 (as amended). Its cannot assure you that auditors' reports for any future fiscal periods will not contain such emphasis of matter, modifications, qualifications and observations.
  • The company intends to utilize a portion of the Net Proceeds for funding its capital expenditure requirements towards (i) the setting up of infrastructure for a research and development facility and Center of Excellence which will be operated by its wholly-owned Subsidiary, Bigtec, and connected office space for the Company, Subsidiaries and Associate, and (ii) purchase of certain plant, machinery and other equipment for Goa Unit I, Goa Unit II and Visakhapatnam Unit. Its inability to successfully undertake such capital expenditure within the estimated cost could have a material adverse effect on the company's business, cash flows, operations, prospects or financial results.
  • Any product liability claims or regulatory actions or imposition of liquidated damages on account of the company's failure to meet the contractual obligations, could have an adverse effect on its business, results of operations, financial condition and cash flows.
  • There have been certain instances of delays in payment of statutory dues by the company in the past. Any delay in payment of statutory dues by the company in future, may result in the imposition of penalties and in turn may have an adverse effect on its business, financial condition, results of operation and cash flows.

Molbio Diagnostics Ltd IPO — frequently asked questions

The Molbio Diagnostics Ltd IPO opens on 10 August 2026 and closes on 12 August 2026. Bidding is accepted from 10:00 AM on the open date until 5:00 PM on the close date. The IPO is available to all eligible investors including retail individual investors, non-institutional investors, and qualified institutional buyers.
The price band for Molbio Diagnostics Ltd IPO is Rs 807 to Rs 807 per share. The lot size is 18 shares per lot, requiring a minimum investment of Rs 14526 at the upper price band. Investors must apply for a minimum of one lot and can apply for up to 18 lots as per SEBI guidelines.
You can apply for the Molbio Diagnostics Ltd IPO through the Chola Securities app or web platform using UPI or ASBA. Log in to your account, navigate to the IPO section, select Molbio Diagnostics Ltd from the open IPOs list, enter your bid quantity and price within the price band, and submit your application. You need an active demat account, a linked bank account, and a valid PAN to apply. Bidding closes on 12 August 2026 at 5:00 PM.
Allotment for Molbio Diagnostics Ltd IPO is scheduled on 13 Aug 2026. Refunds or unblocking of funds for unsuccessful applicants will be processed on 14 Aug 2026. The shares are expected to list on 17 Aug 2026. You can check your allotment status on the Chola Securities IPO page or through the registrar's website using your PAN.
Chola Securities' research team has reviewed the Molbio Diagnostics Ltd IPO based on the company's financials, business model, valuation, and sector outlook. The recommendation is available on this page. Investors are advised to read the full IPO note along with the company's Red Herring Prospectus before making an investment decision.
Yes, you can revise or withdraw your Molbio Diagnostics Ltd IPO bid before the subscription window closes on 12 August 2026 at 5:00 PM. Revisions can include changing the quantity or price within the allowed price band. To withdraw, cancel your application through the platform before the closing time. Once the subscription period ends, no further changes are permitted.
Ready to invest

Apply for the Molbio Diagnostics Ltd through the Chola Securities Mobile & Web App

Bidding closes 09 May 2026 — apply via UPI in under 60 seconds and skip the paperwork.

Apply for IPO Open Demat Account
Chola Securities mobile and web app preview